We are live on
!
Find out more
NTC
NF Trinity Capital Portfolio holdings
AUM
$626M
1-Year Est. Return
3.16%
This Fund
S&P 500
This Quarter
Est. Return
+10.41%
1 Year Est. Return
+3.16%
3 Year Est. Return
+49.61%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$739M
AUM Growth
+$27.3M
(+3.8%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-18.98%
Top 10 Holdings %
Top 10 Hldgs %
63.17%
Holding
47
New
4
Increased
2
Reduced
8
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$5.27M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$4.97M |
| 3 |
Palo Alto Networks
PANW
|
+$4.7M |
| 4 |
Lockheed Martin
LMT
|
+$3.14M |
| 5 |
PayPal
PYPL
|
+$1.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$8.19M |
| 2 |
Baidu
BIDU
|
+$7.08M |
| 3 |
NXP Semiconductors
NXPI
|
+$6.44M |
| 4 |
Universal Display
OLED
|
+$4.47M |
| 5 |
Walt Disney
DIS
|
+$3.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 26.29% |
| 2 | Miscellaneous | 25.59% |
| 3 | Healthcare | 13.48% |
| 4 | Consumer Discretionary | 11.97% |
| 5 | Financials | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARAV
26
DELISTED
Aravive, Inc. Common Stock
ARAV
| $5.23M | 0.71% |
40,816
| – | – |
|
|
27
BioMarin Pharmaceuticals
BMRN
$12.9B
| $4.91M | 0.66% |
+55,900
| New | +$4.97M |
|
|
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.69M | 0.63% |
74,596
| – | – |
|
29
SLB Ltd
SLB
$85.3B
| $4.33M | 0.59% |
55,500
| – | – |
|
|
30
Palo Alto Networks
PANW
$272B
| $3.94M | 0.53% |
+210,000
| New | +$4.7M |
|
31
Viatris
VTRS
$19.4B
| $3.9M | 0.53% |
100,000
| – | – |
|
32
Salesforce
CRM
$213B
| $3.71M | 0.5% |
45,000
| – | – |
|
33
AbbVie
ABBV
$453B
| $3.13M | 0.42% |
48,000
| – | – |
|
|
ZAYO
34
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $2.57M | 0.35% |
78,080
-51,920
| -40% | -$1.66M |
|
|
VNET
35
VNET Group
VNET
$1.81B
| $2.44M | 0.33% |
443,800
| – | – |
|
36
Teva Pharmaceuticals
TEVA
$42.4B
| $1.7M | 0.23% |
53,000
| – | – |
|
|
FLNT
37
Fluent
FLNT
$99.6M
| $906K | 0.12% |
32,467
| – | – |
|
|
38
CALL
NXP Semiconductors
NXPI
$57.5B
| $170K | 0.02% |
+150,000
| New | +$15.2M |
|
|
39
NXP Semiconductors
NXPI
$57.5B
| – | – |
-63,704
| Closed | -$6.44M |
|
Similar funds
SGAM
ACM
TL
DSI
SCA
SHCM
IAS
MFBTD
NF Trinity Capital's Q1 2017 Portfolio in Review
As of Q1 2017, NF Trinity Capital held 47 positions worth $739M, up 3.8% from $712M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
NF Trinity Capital withdrew a net $140M in Q1 2017, closing 1 position and reducing 8 holdings. Its most notable exit was NXP Semiconductors, an estimated $6.44M position sold in full.
By sector, the portfolio is most concentrated in Communication Services at 26% of assets, down from 26% a quarter earlier, followed by Miscellaneous and Healthcare.
Against the trend, NF Trinity Capital opened a new position in Edwards Lifesciences worth $5.28M.
- NF Trinity Capital's largest Q1 2017 buy was Edwards Lifesciences: 168,243 shares worth $5.28M.
- NF Trinity Capital added most to Lockheed Martin in Q1 2017, an estimated $3.14M increase.
- NF Trinity Capital's biggest Q1 2017 reduction was iShares Biotechnology ETF, cutting an estimated $8.19M.
- NF Trinity Capital fully exited NXP Semiconductors in Q1 2017, selling an estimated $6.44M.
- NF Trinity Capital's ten largest holdings make up 63% of its $739M portfolio in Q1 2017.
- NF Trinity Capital opened 4 new positions and closed 1 in Q1 2017.
- NF Trinity Capital's portfolio value rose 3.8% quarter-over-quarter to $739M.
Based on NF Trinity Capital's 13F filing for Q1 2017, filed 5 May 2017.